On June 17, 2025, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital administered the BI770371’s  NCT06806852 trial —developed by Boehringer Ingelheim — to the “first patient in Japan (second patient in the world) ” as part of a global, multicenter First-in-Human Phase 1 Clinical Trial (ClinicalTrials.gov ID: NCT06806852).  The administration took place in Kansai Medical University Hospital.

Study Details | A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone | ClinicalTrials.gov